- In April 2024, Zoetis Inc., a global leader in animal health, launched Simparica Trio® in additional international markets, expanding its reach across Asia and South America. This triple-action parasiticide targets fleas, ticks, and intestinal worms in dogs, offering a comprehensive, once-monthly oral solution. The expansion demonstrates Zoetis’ commitment to advancing animal health and reflects rising global demand for integrated parasite control solutions in companion animals
- In March 2024, Elanco Animal Health Incorporated entered into a strategic partnership with Ginkgo Bioworks to develop next-generation parasiticide products leveraging synthetic biology. This collaboration aims to innovate more targeted, sustainable, and effective treatments for livestock and pets. The partnership highlights the industry's move toward precision parasiticides and underscores Elanco’s focus on long-term R&D-driven growth in the veterinary sector
- In February 2024, Boehringer Ingelheim Animal Health launched a new awareness campaign across Europe promoting NexGard Spectra to emphasize year-round parasite prevention in pets. The initiative involves collaboration with veterinary clinics to educate pet owners on the risks of parasite-borne diseases. This campaign reflects the company's proactive approach to disease prevention and its ongoing investment in the companion animal parasiticide market
- In January 2024, Vetoquinol S.A. announced the acquisition of rights to a new parasiticide molecule targeting resistant strains of gastrointestinal nematodes in livestock. This move strengthens the company's production animal portfolio and aligns with global concerns over anthelmintic resistance. The acquisition reinforces Vetoquinol’s strategic intent to offer advanced, differentiated solutions for large animal health challenges
- In December 2023, Bayer Animal Health, now part of Elanco, received regulatory approval in multiple countries for Advantage XD, a long-acting topical parasiticide for cats. This product offers protection for up to two months against fleas and ticks, addressing pet owner demand for lower-frequency dosing options. The launch supports Elanco’s strategy to expand its premium companion animal product offerings globally
